Edgardo S. Santos, Vice President of Florida Society of Clinical Oncology, shared a post on X:
”Interesting data on a potential biomarker on how to decide between IO mono therapy vs. IO plus chemotherapy. The ProPhet test! It could help us to tailor immunotherapy beyond just PD-L1 expression.”
Source: Edgardo S. Santos/X